209 related articles for article (PubMed ID: 10972984)
1. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
[TBL] [Abstract][Full Text] [Related]
2. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
[TBL] [Abstract][Full Text] [Related]
3. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
4. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
7. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer.
Koike H; Sekine Y; Kamiya M; Nakazato H; Suzuki K
Urology; 2008 Dec; 72(6):1229-33. PubMed ID: 18336887
[TBL] [Abstract][Full Text] [Related]
8. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer.
Partin AW; Getzenberg RH; CarMichael MJ; Vindivich D; Yoo J; Epstein JI; Coffey DS
Cancer Res; 1993 Feb; 53(4):744-6. PubMed ID: 7679049
[TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
11. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
12. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer.
Leman ES; Arlotti JA; Dhir R; Greenberg N; Getzenberg RH
J Cell Biochem; 2002; 86(2):203-12. PubMed ID: 12111990
[TBL] [Abstract][Full Text] [Related]
14. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
[TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of PCNA and p27 in benign prostate hypertrophy and prostate carcinoma].
Lai JS; Xia Q; Zhang XB; Zhao GP; Xu SL; Zheng DS
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):476-8. PubMed ID: 15555337
[TBL] [Abstract][Full Text] [Related]
16. Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer.
Boccardo F; Rubagotti A; Carmignani G; Romagnoli A; Nicolò G; Barboro P; Parodi S; Patrone E; Balbi C
Prostate; 2003 Jun; 55(4):259-64. PubMed ID: 12712405
[TBL] [Abstract][Full Text] [Related]
17. Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications.
Barboro P; Rubagotti A; Boccardo F; Carnemolla B; Darrigo C; Patrone E; Balbi C
Anticancer Res; 2005; 25(6B):3999-4004. PubMed ID: 16309191
[TBL] [Abstract][Full Text] [Related]
18. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
